BIOCON.NS
BIOCON.NS
INE376G01013
BIOCON LIMITED.
Loading chart...

Company Profile

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Related stocks

ANTHEM.NS
ANTHEM.NS • India
ANTHEM BIOSCIENCES LTD
862.3 INR
5B USD 1Y +13.1%
0126Z0.KS
0126Z0.KS • South Korea
SAMSUNG EPIS HOLDINGS
340,500 KRW
6.32B USD
688336.SS
688336.SS • China
SUNSHINE GUOJIAN PHARMACEUTICAL
38.1 CNY
5.11B USD 1Y +4.2%
ONESOURCE.NS
ONESOURCE.NS • India
ONESOURCE SPECL PHARMA L
1,461.3 INR
1.73B USD 1Y -22.7%
002252.SZ
002252.SZ • China
SHANGHAI RAAS
5.06 CNY
4.99B USD 1Y -25.4%
688428.SS
688428.SS • China
INNOCARE PHARMA LTD
28.12 CNY
7.44B USD 1Y +5.2%
9995.HK
9995.HK • China
REMEGEN
70.4 HKD
5.34B USD 1Y -33.7%
1530.HK
1530.HK • China
3SBIO
15.07 HKD
4.76B USD 1Y -47.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
31.4% p.a.
Max Drawdown (5Y)
-51.2%
Sharpe Ratio (5Y)
-0.10
Beta Factor
0.32
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 103.4 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (31.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -58.9% in the extended horizon.
ende